OrthoPediatrics Expects Pandemic to Impact its Scoliosis, Deformity Correction Revenue
By Globe Newswire | 04.13.20
Company insists it will not lay off direct employees due to worldwide crisis.
“As we manage through the challenges presented by the COVID-19 pandemic, our first thoughts go to the healthcare providers, who are selflessly caring for those who are ill. Our priority remains the health and safety of our employees, our customers and patients, and our partners and the communities they serve,” said Mark Throdahl, OrthoPediatrics’ president and CEO. “While our business may be materially impacted over the short-term as elective procedures are temporarily deferred in countries and regions impacted by the pandemic, we have a strong balance sheet that allows us to maintain our operations so we preserve our capability to support our customers and their patients as well as to realize future growth opportunities. Times like this are a test of a company’s leadership and its culture. We are delighted by the spontaneous demonstrations of leadership at all levels throughout OrthoPediatrics as we work remotely but remain cohesive and focused on our strategic priorities. The fundamental prospects of our business remain strong, and once we emerge from this crisis, we will continue to advance our mission to transform the standard of care in pediatric orthopedics.”
Business Performance Update
As hospitals globally postpone elective procedures to generate capacity for treating COVID-19 patients, the company is withdrawing its previously announced 2020 revenue guidance of growth in the range of 22 percent to 24 percent and investment in consignment sets in a range of $19 million to $21 million. OrthoPediatrics anticipates its near-term Deformity Correction and Scoliosis businesses will be significantly impacted following a very strong start to the year. It does not expect the pandemic to impact the Trauma business to the same degree. While elective pediatric orthopedic surgeries cannot be postponed indefinitely and surgeon customers support the company's confidence that there will be a rebound following the crisis, the company cannot determine the duration of the postponement or the timing or extent of pent-up demand. OrthoPediatrics anticipates that the magnitude of the recovery will be limited only by operating room and surgeon scheduling capacity.
The company is proactively responding to the pandemic and working closely with its surgeon base and partners to navigate through this unforeseen event while maintaining operations, including announcing that there will be no layoffs of all its direct employees. To support the anticipation of rescheduled cases following the COVID-19 pandemic, the company is working with its key suppliers to continue building inventories of certain products. Furthermore, OrthoPediatrics has established a Distributor Relief Fund for its 34 domestic and certain international sales agencies, stabilizing the 168 domestic sales consultants who are focused virtually exclusively on OrthoPediatrics.
Meanwhile, OrthoPediatrics has accelerated sales training on new products such as Orthex with remote learning, which will continue to expand during the downturn. In addition to continuing to provide its support to its employees and partners, the company recently utilized its DocMatter website to sponsor the first of many webinars that was attended by several hundred surgeons around the world discussing how to treat pediatric patients in the midst of a COVID-19 pandemic.
The company’s core new product development programs have not been impacted and proceed apace. OrthoPediatrics is also continuing discussions with interesting acquisition opportunities. Additionally, the company continues to receive international regulatory approvals and progress its initiatives to achieve full compliance with the European Union Medical Device Directive, even though the EU has announced that the directive has been postponed for one year. OrthoPediatrics expects to provide an updated outlook in conjunction with its first quarter earnings report.
Balance Sheet Update
As of Dec. 31, 2019, the company had a cash, cash equivalents, and restricted cash balance of $72 million, which includes contributions from a recent financing. On Dec. 11, 2019, the company completed a public offering selling 1,755,500 shares at a price of $36.50 per share. The public offering generated net proceeds of $60 million, after deducting underwriting commissions and offering expenses payable by OrthoPediatrics. The company believes its cash balance is sufficient to fund operations through 2021 and still allow it to take advantage of acquisition opportunities and other strategic transactions. In addition, OrthoPediatrics has the full amount of its $15 million revolving credit facility with Squadron Capital currently available.
2020 Outlook Update
Due to the rapidly evolving environment and continued uncertainties surrounding the impact of COVID-19 and the likelihood that this impact may materially affect the company’s near-term financial performance, OrthoPediatrics is withdrawing its previously announced revenue guidance of growth in the range of 22 percent to 24 percent and investment in consignment sets in a range of $19 million to $21 million.